Similar posts:

• 
  AbbVie Submits Biologics License Application to U.S. FDA of a new botulinum toxin type E

  AbbVie has submitted an application to the FDA for the approval of TrenibotE — the first-in-class botulinum toxin type E. The product demonstrates a record-fast onset of action (8 hours) and a short duration of effect (2-3 weeks), which may change the approach to initial injections in patients who have previously avoided neurotoxins.

• 
  Xeomin – A Botulinum Toxin Product Without Complexing Proteins

  Xeomin has been used in clinical practice for more than 10 years, with over 127,000 people having received injections of this drug, and to date, not a single patient has been identified who failed to show a secondary clinical response.

• 
  Contraindications to Botulinum Toxin

  Millions of botulinum toxin injections have been performed worldwide. However, not all of them were done with contraindications taken into account, and not all patients were satisfied with the results.